Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Instagram Outage Disrupts Thousands of U.S. Users 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
WALTHAM, Mass., Feb. 02, 2016 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will discuss AMAG’s business and financial outlook, strategy and growth prospects at the following investor conferences taking place in February 2016.
- LEERINK Partners 5th Annual Global Healthcare Conference
Presentation: Wednesday, February 10, 2016 at 8:00 a.m. ET*
One-on-one meetings: Wednesday, February 10, 2016
Location: New York, NY - RBC Capital Markets Healthcare Conference 2016
Presentation: Wednesday, February 24, 2016 at 8:30 a.m. ET*
One-on-one meetings: Wednesday, February 24, 2016
Location: New York, NY
*A live webcast of the presentation will be accessible through the Investors section of the company’s website at www.amagpharma.com, and will be archived for 30 days.
About AMAG
AMAG Pharmaceuticals uses its business and clinical expertise to develop and commercialize products that provide clear benefits and improve people’s lives. Based in Waltham, MA, AMAG has a diverse portfolio of products in the areas of maternal health, anemia management and cancer supportive care. AMAG continues to work to expand the impact of these and future products for patients by delivering on its growth strategy, which includes organic growth, as well as the pursuit of products and companies that align with AMAG’s existing therapeutic areas or those that could benefit from its proven core competencies. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals Contact: Maryann Cimino Manager, Corporate Communications & External Affairs 617-498-3375
